Dionysios Neofytos1, Carolina Garcia-Vidal2, Frédéric Lamoth3,4, Christoph Lichtenstern5, Alessandro Perrella6,7, Jörg Janne Vehreschild8,9,10. 1. Service des Maladies Infectieuses, Hôpitaux Universitaires de Genève, Rue Gabrielle-Perret-Gentil 4, Geneva, Switzerland. Dionysios.Neofytos@hcuge.ch. 2. Servicio de Enfermedades Infecciosas, Hospital Clínic de Barcelona-IDIBAPS, Universitat de Barcelona, FungiCLINIC Research group (AGAUR), Barcelona, Spain. 3. Infectious Diseases Service, Department of Medicine, Lausanne University Hospital, 1011, Lausanne, Switzerland. 4. Department of Laboratories, Institute of Microbiology, Lausanne University Hospital, Lausanne, Switzerland. 5. Department of Anaesthesiology, Heidelberg University Hospital, Im Neuenheimer Feld 110, Heidelberg, Germany. 6. VII Department of Infectious Disease and Immunology, Hospital D. Cotugno, Naples, Italy. 7. CLSE-Liver Transplant Unit, Hospital A. Cardarelli, Naples, Italy. 8. Medical Department II, Hematology and Oncology, University Hospital of Frankfurt, Frankfurt, Germany. 9. Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany. 10. German Centre for Infection Research, partner site Bonn-Cologne, University of Cologne, Cologne, Germany.
Abstract
BACKGROUND: Invasive aspergillosis (IA) is a rare complication in solid organ transplant (SOT) recipients. Although IA has significant implications on graft and patient survival, data on diagnosis and management of this infection in SOT recipients are still limited. METHODS: Discussion of current practices and limitations in the diagnosis, prophylaxis, and treatment of IA and proposal of means of assessing treatment response in SOT recipients. RESULTS: Liver, lung, heart or kidney transplant recipients have common as well as different risk factors to the development of IA, thus each category needs a separate evaluation. Diagnosis of IA in SOT recipients requires a high degree of awareness, because established diagnostic tools may not provide the same sensitivity and specificity observed in the neutropenic population. IA treatment relies primarily on mold-active triazoles, but potential interactions with immunosuppressants and other concomitant therapies need special attention. CONCLUSIONS: Criteria to assess response have not been sufficiently evaluated in the SOT population and CT lesion dynamics, and serologic markers may be influenced by the underlying disease and type and severity of immunosuppression. There is a need for well-orchestrated efforts to study IA diagnosis and management in SOT recipients and to develop comprehensive guidelines for this population.
BACKGROUND:Invasive aspergillosis (IA) is a rare complication in solid organ transplant (SOT) recipients. Although IA has significant implications on graft and patient survival, data on diagnosis and management of this infection in SOT recipients are still limited. METHODS: Discussion of current practices and limitations in the diagnosis, prophylaxis, and treatment of IA and proposal of means of assessing treatment response in SOT recipients. RESULTS: Liver, lung, heart or kidney transplant recipients have common as well as different risk factors to the development of IA, thus each category needs a separate evaluation. Diagnosis of IA in SOT recipients requires a high degree of awareness, because established diagnostic tools may not provide the same sensitivity and specificity observed in the neutropenic population. IA treatment relies primarily on mold-active triazoles, but potential interactions with immunosuppressants and other concomitant therapies need special attention. CONCLUSIONS: Criteria to assess response have not been sufficiently evaluated in the SOT population and CT lesion dynamics, and serologic markers may be influenced by the underlying disease and type and severity of immunosuppression. There is a need for well-orchestrated efforts to study IA diagnosis and management in SOT recipients and to develop comprehensive guidelines for this population.
Authors: C Lim; J B Seo; S-Y Park; H-J Hwang; H J Lee; S-O Lee; E J Chae; K-H Do; J-W Song; M Y Kim; S-H Kim Journal: Clin Radiol Date: 2012-07-04 Impact factor: 2.350
Authors: Mila Krel; Vidmantas Petraitis; Ruta Petraitiene; Mohit Raja Jain; Yanan Zhao; Hong Li; Thomas J Walsh; David S Perlin Journal: Antimicrob Agents Chemother Date: 2014-03-31 Impact factor: 5.191
Authors: Judith van Paassen; Anne Russcher; Astrid Wm In 't Veld-van Wingerden; Paul E Verweij; Eduard J Kuijper Journal: Euro Surveill Date: 2016-07-28
Authors: Gerard Moreno; Alejandro Rodríguez; Luis F Reyes; Josep Gomez; Jordi Sole-Violan; Emili Díaz; María Bodí; Sandra Trefler; Juan Guardiola; Juan C Yébenes; Alex Soriano; José Garnacho-Montero; Lorenzo Socias; María Del Valle Ortíz; Eudald Correig; Judith Marín-Corral; Montserrat Vallverdú-Vidal; Marcos I Restrepo; Antoni Torres; Ignacio Martín-Loeches Journal: Intensive Care Med Date: 2018-08-03 Impact factor: 17.440
Authors: Tomasz Urbanowicz; Michał Michalak; Anna Olasińska-Wiśniewska; Bartłomiej Perek; Michał Rodzki; Hanna Wachowiak-Baszyńska; Marek Jemielity Journal: Medicina (Kaunas) Date: 2021-11-27 Impact factor: 2.430